A novel SARS-CoV-2 subunit vaccine engineered on an immune-activating platform technology
While there are several SARS-CoV-2 vaccines currently available, additional options must be provided that are safe, effective, and affordable for the entire global population. We have developed a novel immune activating platform technology that will fill this need. This recombinant platform protein...
Gorde:
Egile Nagusiak: | , , |
---|---|
Formatua: | Liburua |
Argitaratua: |
Taylor & Francis Group,
2022-11-01T00:00:00Z.
|
Gaiak: | |
Sarrera elektronikoa: | Connect to this object online. |
Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|
Internet
Connect to this object online.3rd Floor Main Library
Sailkapena: |
A1234.567 |
---|---|
Alea 1 | Eskuragarri |